Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Mitochondrial Complex I Deficiency and Neurodegenerative Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NDUFA2 drug discovery.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NDUFA2 Recombinant Protein (Wild-Type & Custom Pathogenic Mutants) — High purity (>95%), Endotoxin <1 EU/µg. Sequence verified. Including native MTS. | View NDUFA2 Products |
| Gene Delivery | NDUFA2 Promise-ORF / Lentivirus Premade Particles — Full-length ORF with native MTS for stable cell line construction and mitochondrial import studies. | View NDUFA2 Products |
| Benchmark Ab | Anti-NDUFA2 Recombinant Monoclonal Antibody — Validated for Western blot, ELISA, Blue Native PAGE, and immunofluorescence. | View NDUFA2 Products |
| Validator | NDUFA2 siRNA Set (3 unique sequences) — For knockdown verification and specificity controls in cell-based Complex I assays and OCR measurements. | View NDUFA2 Products |
| Related Target A | NDUFS1 — Core catalytic subunit of Complex I; essential assembly scaffold and electron transfer hub. | View NDUFS1 Products |
| Related Target B | NDUFS4 — Accessory subunit with overlapping Leigh syndrome phenotype; stabilizes N-module. | View NDUFS4 Products |
| Related Target C | SDHA — Complex II subunit; clinically relevant bypass pathway when Complex I flux is compromised. | View SDHA Products |
| Related Target D | LRRK2 — Parkinson’s disease-associated kinase linked to mitochondrial dysfunction and mitophagy pathways. | View LRRK2 Products |
| Related Target E | NDUFV1 — Flavoprotein of N-module accepting electrons from NADH; direct functional neighbor to NDUFA2. | View NDUFV1 Products |
| Related Target F | NDUFA9 — Required for Complex I stability and supercomplex formation with Complex III. | View NDUFA9 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mitochondrial Import & Localization | Full-length ORF with native MTS cloned into lentiviral backbone; HEK293 expressed for mammalian compatibility. Verified by immunofluorescence colocalization with MitoTracker. |
| Disease-Mutant Chaperone Screening | Custom pathogenic mutant proteins available (>95% purity, sequence verified, endotoxin <1 EU/µg) for thermal shift assays (DSF) and binding studies. |
| Complex I Assembly & Activity Reconstitution | High-purity NDUFA2 antigen suitable for Blue Native PAGE (BN-PAGE) and co-immunoprecipitation; enables assessment of 980 kDa holoenzyme assembly and NADH:DB oxidoreductase activity. |
| Specificity vs. Complex I Subfamily | Strict sequence specificity confirmed by LC-MS/MS; no cross-reactivity with NDUFS, NDUFV, or NDUFB families. |
| Functional Knockdown Controls | Validated siRNA pool included for Seahorse XF OCR rescue experiments, ensuring target-dependent phenotypes. |
| Intracellular Protein Stability | Recombinant proteins optimized for stability and >95% purity, low endotoxin, suitable for cell-based uptake and stability assays. |
| Lack of Controls | Recombinant antibodies included for standardized bench-marking across assays. |
Live NDUFA2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Resistance & Mitochondrial Disease Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for NDUFA2 therapeutics is intensifying within the context of mitochondrial diseases, such as Leigh syndrome, and complex neurodegenerative disorders. First-generation approaches focusing on metabolic modulation and antioxidant strategies are giving way to precision genetic interventions (AAV-mediated gene supplementation) and highly selective small-molecule bioenergetic modulators and chaperones. The next wave of R&D is expected to focus on stoichiometry-correct Complex I subunit replacement, allosteric stabilization of disease-associated mutant monomers, and targeting the Complex I N-module for cancer metabolism disruption. As mitochondrial medicine matures, key players including academic consortia, rare disease foundations, and biotechs (BridgeBio, Reneo Pharma, Stealth BioTherapeutics) are advancing preclinical programs toward IND-enabling stages. By 2026–2027, the first NDUFA2-targeted gene therapy for Leigh syndrome may enter Phase II trials.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV/MTS-ORF) | Academic consortia, BridgeBio, Stealth BioTherapeutics | Leigh Syndrome, Mitochondrial Complex I Deficiency | Mitochondrial localization & import validation (Need high-purity NDUFA2 antibody for IF/WB; MTS-bearing Lentivirus for cell line construction) |
| Small-Molecule Chaperone | Preclinical biotech programs | Neurodegeneration, Rare Metabolic Disease | Mutant vs WT protein stability assays (Need high-purity recombinant variants for DSF/SPR) |
| Small-Molecule Inhibitors | Calithera Biosciences, AstraZeneca | Solid Tumors (Metabolic Synthetic Lethality) | Complex I activity & selectivity assay (Need recombinant NDUFA2 for N-module reconstitution) |
| Metabolic Modulators | Mitochondrial Specialists | Oncology, Aging | Cellular respiration models (Need isogenic cell lines with NDUFA2 modulation) |
| Protein Transduction (Research) | Academic consortia (MITO-TAMP) | Ischemia-Reperfusion Injury, Cardiac Protection | Membrane penetration & assembly validation (Need full-length NDUFA2 protein standards) |
Key Mutation in NDUFA2
A somatic mutation (UniProt VAR_036174) has been documented in a breast cancer sample, indicating a potential role in oncogenesis. Researchers studying NDUFA2 in cancer metabolism should consider mutation-specific functional assays. Note: additional pathogenic mutations linked to Leigh syndrome, such as R68H and V110M, are commonly studied in mitochondrial disease contexts.